chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Lightheadedness- pale - appeared dazed- HR 59 B/P difficult to hear- pulse weak - monitored for approx. 30minutes BP high to 90/60 and HR 66- 02 Sats are 100% encouraged fluids and a meal- he was smiling, joking, feeling better when he left the site
After the first dose the patient started to bleed (uterine bleeding) couple hours after the vaccine administration. Ultrasound located the source in uterine ? possible blood clot (the bleeding has stopped by itself after 6 days. After the second dose it happened again, the bleeding has not stopped on day 8 (and counting). Diagnosis: uterine bleeding ? unknown nature.
Delirium; Fainting episode with convulsions; Fever with Chills; Nausea; Dizziness and disoriented; Dizziness and disoriented; This is a spontaneous report from a contactable consumer (patient). A 25-year-old female patient (not pregnant) received first dose of bnt162b2 (Batch/Lot Number: EN6207), via an unspecified route of administration, administered in left arm on 18Mar2021 08:30 as single dose for covid-19 immunization. Medical history included cystitis interstitial from an unknown date and unknown if ongoing. Concomitant medications included ethinylestradiol, ferrous fumarate, norethisterone acetate (LO LOESTRIN FE) taken for an unspecified indication, start and stop date were not reported. The patient experienced delirium, fainting episode with convulsions, fever with chills, nausea, dizziness and disoriented on 18Mar2021 09:00. No other vaccine in four weeks. The adverse event was not resulted in a visit to doctor or other healthcare professional office/clinic or Emergency room/department or urgent care. No treatment received. The outcome of events was resolving. No Covid prior vaccination. No Covid tested post vaccination. Not Known allergies.
Patient received vaccine BUD. Vaccine expired on 7/7/22 and was given to pt on 7/19/22
Patient came for Covid booster.  Patient fainted and was laid down on a cot at approxomately 2:42 pm.   Patient vitals were checked at 2:43 sytolic 102 diastolic 66 hr 80.   Patient vitals rechecked at 252 pm Systolic 97 Diastolic 66 HR 78.  At 3:03 pm  pm, patient's syncope resolved and was able to leave with her father.
March 2021: Arm pit rash, stoped sweating, extreme fatigue, back pain June 2021 heat intolerance, decreased thyroid level (0.02), heart palpitations, still not sweating, extreme fatigue October 2021: uncontrolled blood pressure, dizziness, extreme fatigue, weight gain, weird headache, tachycardia, SOB, inability to exert self for exercise, brain fog
severe pain, burning and  swelling of entire arm.  The arm was very warm and the triceps was red and tender. My elbow swelled up to size of a baseball and the joint hurt.  I could hardly move my arm-the muscles wouldn't contract.  The pain and bicep swelling started 7 pm the day of vaccination.  Pain continued the next day (friday) with severe burning, swollen and red along triceps. On Saturday morning my elbow was swollen,  warm, painful and triceps were sore.  I contacted a doctor(virtual visit) on Sunday-i was afraid I had an infection, prescribed Keflex 500mg 4 times/day. Swelling, redness subsided so didn't take it. Took over 7 days for arm to feel better.
I woke up & noticed a red blotch over my left cheek & a couple of weeks passed & it spread all over my face it was itchy & hurt to the touch, so I went to my oncologist and was told he didn't think it was an adverse reaction to vaccine. I have had multiple biopsies on my face as of today & also my back.
mom states child woke feeling very hot this AM @ 1AM w/what seemed to be involuntary jerky movements every few seconds this episode lasted about 20min;taken to ER;
Vaccination adverse reaction; Flu like symptoms; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Vaccination adverse reaction) and INFLUENZA LIKE ILLNESS (Flu like symptoms) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Ulcerative colitis.    No Medical History information was reported.   On 23-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 19-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Vaccination adverse reaction) and INFLUENZA LIKE ILLNESS (Flu like symptoms). At the time of the report, IMMUNISATION REACTION (Vaccination adverse reaction) and INFLUENZA LIKE ILLNESS (Flu like symptoms) was resolving.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Hepatic enzyme increased: increased (High) Increased.         No concomitant medications were provided by the reporter.  Patient had received the co-suspect product HUMIRA with daily dose of CF.  No treatment medications were provided by the reporter.
Headache, Muscle aches, a "buzzy" feeling in the body, GI upset, brain fog, exhaustion upon arising and in the evenings. Soreness at injection site lasted 2 days, the other symptoms lasted four full days.
Expired dose administered to patient; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired dose administered to patient) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Nov-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired dose administered to patient). On 05-Nov-2021, EXPIRED PRODUCT ADMINISTERED (Expired dose administered to patient) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication reported. No treatment information was provided.    Most recent FOLLOW-UP information incorporated above includes: On 09-Nov-2021: Follow up document contains no new information On 09-Nov-2021: Follow up document contains no new information
patient received PNEUMOVAX 23 1st dose on 6/15/2017 and 2nd dose on 6/8/2018; This spontaneous report has been received from a medical student and refers to a patient of an unknown age and gender.  The patient's medical history, current conditions, concomitant therapies, and previous drugs reactions or allergies were not reported.  On 15-JUN-2017, the patient wqas vaccinated with the first dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23), on 08-JUN-2019 the patient received a second dose of pneumococcal vaccine, polyvalent (23-valent) (PNEUMOVAX23) as prophylaxis (doses, lot #s, expiry dates, and routes of administration were not provided) (product use issue).
patient had a black and blue mark on the injection site; bright red face and breasts like cherry red; big welt on the arm; Initial information received on 01-Feb-2021 regarding an unsolicited valid non-serious case from non-healthcare professional.  This case involves a 65 years elderly female patient who had black and blue mark on the injection site (injection site discolouration), bright red face and breasts like cherry red (erythema) and big welt on the arm (urticaria), after receiving INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [FLUZONE HIGH-DOSE QUADRIVALENT].  The patient's past vaccination(s) included Prevnar 13 given in SEP-2020 for prophylactic vaccination and had delayed anaphylactic reaction.  The patient's past medical history, medical treatment(s), concomitant medication(s) and family history were not provided.  On an unknown date in November 2020, the patient received a dose of suspect INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE [lot number and expiry date not reported] via unknown route in the left arm for prophylactic vaccination.  On an unknown date in November 2020, the patient developed a non-serious black and blue mark on the injection site (injection site discolouration), bright red face and breasts like cherry red (erythema) and big welt on the arm (urticaria) on the next morning, following the administration of INFLUENZA QUADRIVAL A-B HIGH DOSE HV VACCINE.  No laboratory data reported.  It was not reported if the patient received a corrective treatment.  The patient recovered from all the events as it is reported that it took 3-4 weeks for urticaria and erythema to go away and injection site discolouration to fade away too.  There will be no information on the batch number to be requested for this case.
This case was reported by a nurse via call center representative and described the occurrence of injection site erythema in a female patient who received SHINGRIX. On 15th March 2018, the patient received SHINGRIX. In March 2018, less than a month after receiving SHINGRIX, the patient experienced injection site erythema. On 16th March 2018, the patient experienced urticarial rash, nausea, chills, headache and slight temperature. The patient was treated with BENADRYL and Cortisone (NOS). On an unknown date, the outcome of the injection site erythema and slight temperature were unknown and the outcome of the urticarial rash was recovering/resolving and the outcome of the nausea, chills and headache were recovered/resolved. It was unknown if the reporter considered the injection site erythema and slight temperature to be related to SHINGRIX. The reporter considered the urticarial rash, nausea, chills and headache to be almost certainly related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. This case was reported by the Nurse Practitioner. The patient details, lot number or expiry date was not provided. The healthcare professional reported that 1 day after the patient received a dose of SHINGRIX in left arm and developed urticarial rash approximately 7 cm wide, a mild headache, nausea, chills and a low grade temperature of 99 degrees Fahrenheit. Injection site now just red not raised anymore. The patient took BENADRYL and applied cortisone to area.
Shivers Fever Headache Muscle Aches Redness, warmth and pain below injection site
Inconsolable crying lasting over 1 hour at a time. Persisted off and on until 5/18/2012.
This spontaneous report was received from a physician via a company representative and refers to a female patient of unknown age. The patient's medical history, concomitant medications and concurrent conditions were not reported. On an unknown date in approximately 2015 (reported as about two years ago), the patient was vaccinated with ZOSTAVAX (dose, route, anatomical location, lot# and expiration date were not reported) for prevention of shingles. On an unknown date in approximately 2017 (reported as about two years after receiving ZOSTAVAX), the patient developed shingles. The outcome of the event and the relatedness between the event and ZOSTAVAX were not reported.
Significant increase in symptoms of neuromuscular problems. I had to seek medical treatment. The increase in symptoms is slowly getting better over the last three weeks.
Reporting administration error as per immunization system. We contacted Pfizer for expiration dates, Pfizer vaccine specialist advised expiration dates and deemed vaccine viable at the time of vaccine administration. Pfizer vaccine vials only include manufatuarer dates on the box and vials. Therefore we contacted Pfizer to attain expiration dates directly from them.  No adverse reaction reported from patietn at the time of the vaccination and no adverse reaction reported since vaccine given.
appears to be my vastus lateralls muscle. I couldn't feel anything in that part of my leg, only pressure when I pressed the area; After the numbness went away my leg tingles periodically in the same area; This spontaneous case was reported by a patient and describes the occurrence of HYPOAESTHESIA (appears to be my vastus lateralls muscle. I couldn't feel anything in that part of my leg, only pressure when I pressed the area) in a 58-year-old female patient who received mRNA-1273.815 (SPIKEVAX 2023-2024) for COVID-19 prophylaxis. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 09-Nov-2023, the patient received dose of mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) 1 dosage form. On 11-Nov-2023, the patient experienced HYPOAESTHESIA (appears to be my vastus lateralls muscle. I couldn't feel anything in that part of my leg, only pressure when I pressed the area) (seriousness criterion hospitalization) and PARAESTHESIA (After the numbness went away my leg tingles periodically in the same area). In November 2023, HYPOAESTHESIA (appears to be my vastus lateralls muscle. I couldn't feel anything in that part of my leg, only pressure when I pressed the area) had resolved. At the time of the report, PARAESTHESIA (After the numbness went away my leg tingles periodically in the same area) had not resolved.        The action taken with mRNA-1273.815 (SPIKEVAX 2023-2024) (Intramuscular use) was unknown.       No concomitant medication was reported.  within 24 hours of getting the shot her leg became numb, appeared to be her vastus lateralls muscle. She couldn't feel anything in that part of her leg, only pressure when she pressed the area. It was numb for approximately 2-3 days.  After the numbness went away her leg tingles periodically in the same area, sort of like when foot falls asleep, same feeling. The tingling continues as of today, but the numbness was gone so this was partially resolved. It was unknown if the patient experienced any additional symptoms/events.  No treatment information was reported. Company comment: This spontaneous case concerns a 58-year-old female patient, with no medical history reported, who experienced the unexpected and serious (hospitalization) event of HYPOAESTHESIA, and the unexpected and non-serious event of PARAESTHESIA, 2 days after an unspecified dose of mRNA-1273.815 (SPIKEVAX 2023-2024) vaccine. She experienced numbness for approximately 2-3 days. After the numbness recovered tingling continues periodically in the same area. No details of previous doses were provided. No treatment information was reported. No further clinical information was available for medical review. The benefit-risk relationship of mRNA-1273.815 (SPIKEVAX 2023-2024) vaccine is not affected by this report.
she had developed a blood clot in her lungs; coughing up blood; This is a spontaneous report from a contactable consumer (patient). A 51-year-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration (at the age of 51-years-old), administered in Deltoid Right (reported as "right upper arm shoulder") on 07Apr2021 09:45 (Lot Number: EW0150) as 2nd dose, single for COVID-19 immunization. Medical history included eosinophilic granulomatosis with polyangiitis (Churg Strauss syndrome) and asthma. The patient's concomitant medications were not reported. The patient previously received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in Right upper arm shoulder on 17Mar2021 (Lot Number: EN6208) as 1st dose, single for COVID-19 immunization. The second dose of the vaccine the patient received on 07Apr2021 and she had a great experience with it and nothing happened. Then on 30Apr2021, patient experienced coughing up blood, which required a visit to the Emergency Room. She was admitted in the hospital on 30Apr2021, and they discovered a clot in her lung she is surprised to find out because she is very healthy individual. She had got out of the hospital yesterday (03May2021) for a blood clot in her lungs where the hospital did a bronchoscopy, they cut it out. The blood clot was big and deep. They did a test to see if the blood clot is from her rare disease which it was not so the doctors have no idea what caused the blood clot. She did her research and the only thing that had changed was she got the vaccine and then she also just switched to a different inhaler for her asthma but she has taken it before. The doctors do not think it is any of the two things. The doctor does not know what caused the blood clot and she saw there has been 35 cases reported of a rare blood clot and according to her findings. She was hospitalized for 3 nights (when discovered a clot in her lung) from 30Apr2021 to 03May2021. The blood clot was removed Sunday 02May2021. She had blood work done prior to the vaccine and her count was excellent. The patient underwent lab tests and procedures which included blood test: her count was excellent prior to the vaccine, blood test: it was not (from her rare disease), bronchoscopy: blood clot, electrocardiogram: well, full blood count: well, liver function test: well, thyroid function test: it need to be adjusted: all on unspecified dates. The patient reported that, "hospital where my blood drawn, oh actual testing too many to mention, CBC (complete blood count), ECG (electrocardiogram), Liver function lot of different test. Everything was well except my thyroid it need to be adjusted am taking care of it. It was Saturday prior to the second shot maybe I don't know." Therapeutic measures were taken as a result of the events which included bronchoscopy, they cut it out, they did a catheter in upper part of left lung. The outcome of the events was recovered on 02May2021. There were no prior vaccinations (within 4 weeks). No adverse events following prior vaccinations.
Anaphylaxis, hives, whips around waist and butt, itching ,swollen lips . Was given epic Pen and Benadryl , Pepsi?s and steroids 24 hours and it returned when to doctors office and received another steroid shot
Patient has experienced redness, soreness, swelling, and the right arm is warm to the touch. Patient stated that they felt some pain in their right shoulder upon movement. She has applied ice to her arm and has also taken Naproxen to decrease the swelling.
Patient was hospitalized from 4/11-4/13/15 due to leg pain and limping. Sepsis/cellulitis was ruled out, did have fever 2 days following injection. MRI was wnl, dx was superficial fasciitis and focal Myositis inflammatory vs infectious. Patient has Wiskott-Aldrich disease.
This case was reported by a pharmacist via call center representative and described the occurrence of weakness in a 70-year-old female patient who received SHINGRIX (batch number XC534, expiry date 4th July 2020). On 27th March 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On an unknown date, less than a month after receiving SHINGRIX, the patient experienced weakness, injection site pain and tingling of extremity. On an unknown date, the outcome of the weakness, injection site pain and tingling of extremity were unknown. It was unknown if the reporter considered the weakness, injection site pain and tingling of extremity to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX in left deltoid. The patient received SHINGRIX in left deltoid. The patient experience soreness and tenderness at the injection site. On 20th April 2018, the patient notified the pharmacist that they began experiencing weakness tingling in the arm which was not improving. The patient had not been seen in the emergency room, or hospitalized at the time of the report, but the health care professional reported that they would refer her to her doctor if the symptoms continued. The health care professional was unsure when the initial symptoms began but stated that the patient returned to the pharmacy a few days after receiving the vaccine with soreness and tenderness. The patient's symptoms were not considered disabling or life threatening. The caller was pharmacist who reported original event. The caller was requesting a copy of the original adverse event report or any other documentation from that report that can be provided to him to share with the involved patient per the request of the patient. This case has been linked with US2018069589, reported by the same reporter.
Patient was given a chickenpox vaccine at school. Shortly after having that vaccine the entire right side of her face got paralyzed. Neither she was able to close her eye, nor move her mouse or nose. Patient's mom took her to ER, they checked patient for a stroke and some other things, and told to contact pediatrician.
patient reports that she received the Materna Covid 19 vaccine on March 19, 2021.  Approximately one week after she developed asthma symptoms which were more severe than usual and generalized hives.  She was treated with steroids and antibiotics,states she was diagnosed with viral infection.  On April 26, 2021 she received the second dose of Materna Covid 19 vaccine and experienced generalized bruising, and slight respiratory issue.  States she took Benadryl and steroids.  Symptoms improved.
Following say I had body ache and headache that began upon awakening at 9 am; relieved with ibuprofen. Headache returned in the afternoon and by evening I had developed 99.2F fever, chills, and muscle aches, headache and nausea. This was relieved with Tylenol.
Heart palpitations, anxiety,(felt this prior to today). 126/84, 87,  6, 99%, BGL 176
Started experiencing what felt like a heart flutter frequently throughout the day following the vaccine.  I continued to monitor it and could feel my heart pounding while doing low effort activities (working at my desk, watching tv) along with walking and other activity all throughout the day. After three days of this continuing and experiencing a fluttering feeling/heartbeat in my throat regularly, I went to urgent care (on Friday - three days post injection). Blood pressure was high for me at 132/80. ECG was run and came back normal indicating no heart arrhythmia. Heat palpitations were diagnosed.
This case was considered medically important. Information regarding Prevenar was received from a consumer and verified with a healthcare professional, regarding a 7-year-old male patient who experienced autism. The patient received the third dose of Prevenar on 15-Oct-2001. The patient also received the third dose of Recombivax-Hb (Merck) and the third dose of Infanrix (GlaxoSmithKline) on 15-Oct-2001. The patient's older brother also developed autism (date unspecified). See related case US-WYE-H03499608. Product was administered on 15-Oct-2001. Additional suspect vaccines included Acel-Immune/Wyeth, Infanrix (GlaxoSmithKline), Recombivax-Hb (Merck), Pedvax-Hib (Merck), Poliomyelitis Vaccine Inactivated (manufacturer unknown), Hib-Titer/Wyeth, Varivax (Merck), M-M-R II (Merck) and Ipol (Aventis). Concomitant medications were not reported. The patient experienced autism in May-2005. The patient has not recovered. Neuropsychological test (results: not available) and hair metal test (results: not available) were done on an unspecified date. See related case(s): US-WYE-H03499608 (adverse event, expedited). No additional information was available at the time of this report.
Initial and follow up information has been received from a nurse practitioner concerning a 22 year old female student with no acute illness or chronic disease and food allergy to eggplant who on 08 Nov 2006, at 14:00, was vaccinated witha second dose of Gardasil. It was reported that the patient pulled away during adminstration due to "strange sensation" and a significant amount medication went down the patient's arm. It was estimated that only one third to one half of the dose was administered. It was reported that the patient had to repeat the second. On 08 Nov 2006, the patient recovered from the event.  No further information is available.